Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Down 56.7% in January

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 6,808 shares, a decline of 56.7% from the December 31st total of 15,724 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 24,455 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 24,455 shares, the short-interest ratio is currently 0.3 days. Currently, 0.2% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Scinai Immunotherapeutics presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC increased its position in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the quarter. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 58.41% of the company’s stock.

Scinai Immunotherapeutics Trading Down 5.8%

NASDAQ:SCNI traded down $0.06 during trading hours on Thursday, hitting $0.97. The company had a trading volume of 52,076 shares, compared to its average volume of 57,357. Scinai Immunotherapeutics has a 1 year low of $0.61 and a 1 year high of $6.18. The company has a market cap of $3.09 million, a P/E ratio of -0.10 and a beta of 1.72. The company has a 50-day moving average of $0.91 and a 200 day moving average of $1.30.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.